Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Maria Masvidal
Observed names:
M. Masvidal,
M. Masvidal Hernandez,
M., Masvidal,
María Masvidal,
Masvidal, Maria
Institutions:
Institut de Recerca Biomèdica Catalunya Sud,
Hospital Universitari Sant Joan de Reus,
Universitat Rovira i Virgili
Observed institutions:
Institut de Recerca Biomèdica Catalunya Sud,
Hospital Universitari Sant Joan de Reus,
Universitat Rovira i Virgili
ORCID:
0009-0009-9160-0442
Observed ORCID:
0009-0009-9160-0442
OpenAlex ID:
A5041078682
Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting
2022
·
Margarita Romeo
, Marta Gil-Martín
, et al.
·
Cancers
·
26
PDF
An ambispective, real-world multi-center study of DOstarlimab in patients with Recurrent or Advanced DNA mismatch repair deficient/microsatellite instability-high endometrial cancer (GEICO 120-R/DORA study)
2025
·
Alejandro Gallego
, Ainhoa Madariaga
, et al.
·
International Journal of Gynecological Cancer
·
4
Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors
2026
·
Lucy Haggstrom
, Yeh Chen Lee
, et al.
·
JAMA Oncology
·
2
PDF
Atypical Presentation of an Ovarian Yolk Sac Tumor in an 80-Year-Old Woman: A Case Report and Review of the Literature
2024
·
Vanessa Maldonado
, María Masvidal
, et al.
·
Case Reports in Oncology
·
2
PDF
Ovarian Cancer Retrospective European (O'CaRE) study: first-line outcomes by number of risk factors for progression
2024
·
Jonathan Krell
, Danielle Shaw
, et al.
·
Future Oncology
·
2
PDF
Characterization of thrombosis risk in ambulatory patients with cancer: results of the observational, prospective, multicenter CARTAGO study
2024
·
Javier Trujillo-Santos
, Ignacio García-Escobar
, et al.
·
The Oncologist
·
1
2022-RA-1505-ESGO Ovarian cancer retrospective European (O’CaRE) observational study: analysis of first-line (1L) outcomes in patients with ovarian cancer (OC) stratified by number of risk factors for progression
2022
·
Jonathan Krell
, Thumulurua K Madhuri
, et al.
·
International Journal of Gynecological Cancer
·
1
PDF
Five Years Of Real-Life Data In Gynaecological Cancers: A Multicenter Clinical Registry With Associated Samples (GEICO 81-T)
2025
·
Fernando Gálvez
, Gloria Marquina
, et al.
·
International Journal of Gynecological Cancer
452 Primary analysis of GEICO 120/DORA, a real-world multicentre study of dostarlimab in patients with recurrent or advanced DNA mismatch repair deficient/microsatellite instability-high (DMMR/MSI-H) endometrial cancer
2024
·
Alejandro Gallego
, Ainhoa Madariaga
, et al.
·
International Journal of Gynecological Cancer
148P Descriptive study of mutation status and clinical phenotype in breast cancer patients of South Catalonia
2022
·
A. Cochs
, M. Rodriguez Balada
, et al.
·
Annals of Oncology
748P Real-world-data (RWD) on platinum (Pt)-based chemotherapy (CT) after PARP inhibitors (PARPi) in high-grade serous (or endometrioid) ovarian cancer (HGSEOC)
2021
·
M. Romeo Marin
, M. Gil-Martin
, et al.
·
Annals of Oncology
PDF
Show more works
View as search
Works count:
13
Citation count:
38
H-index:
2
I10-index:
1
Year
Topic
Type